MDMA-Authorised Prescriber approval PTSD

Emyria Ltd (ASX:EMD) has received Authorised Prescriber approval from the Therapeutic Goods Administration (TGA) for MDMA-assisted therapy in treating post-traumatic stress disorder (PTSD) This means Emyria’s specialist psychiatrist can prescribe MDMA under a strict regulatory framework for PTSD care.

This is a significant milestone, as MDMA-assisted therapy is being explored as a treatment for PTSD, with multiple Phase 3 clinical trials conducted in the USA. The approval allows Emyria to expand its service offerings beyond clinical trials and into real-world treatment